1. What's New in PAH?

3. Program Themes

4. Important Advances in PAH

5. Evolution of Clinical Trials in PAH

6. Challenges With Clinical Trial Design

7. Growing Use of Combination Therapy

8. AMBITION Trial: Ambrisentan and Tadalafil in Patients With PAH

9. Trends in Treatment Options for a Newly Diagnosed Patient in WHO FC II or III

10. AMBITION Trial: First Adjudicated Clinical Failure by Subgroups

11. Determinants of Prognosis in PAH

12. GRIPHON Trial Design

13. GRIPHON Trial Clinical Efficacy

14. GRIPHON Trial Treatment Effect by Subgroup

15. Effective Communication With Patients

16. Pharmacologic Agents for PAH 3 Pathways

17. Initial Triple Therapy

18. Opportunity to Incorporate PROs

19. PAH-SYMPACT

20. World Symposium on Pulmonary Hypertension, February 2018

21. Perspectives of 2 Experts

22. Concluding Remarks

23. Abbreviations